biostudies-literatureUnknownStish BJNCI NIH HHS<h4>Purpose</h4>Hot flashes are a common side effect reported by men receiving androgen-deprivation therapy (ADT) for the treatment of prostate cancer. We sought to determine whether oxybutynin could improve hot flash symptoms in men with prostate cancer.<h4>Patients and methods</h4>Patients with prostate cancer receiving a stable regimen of ADT with at least 28 hot flashes per week were randomly assigned to receive either oxybutynin 2.5 mg twice daily, oxybutynin 5 mg twice daily, or matching placebo for 6 weeks. The primary end point was the change in patient-reported hot flash scores since baseline at 6 weeks. Additional outcomes included incidence of adverse events (AEs), changes since baseline in Hot Flash-Related Daily Interference Scale (HFRDIS) scores, and patient-reported symptomsJournal of clinical oncology : official journal of the American Society of Clinical OncologyJCO2501486https://www.ebi.ac.uk/biostudies/studies/S-EPMC12871868biostudies-literatureAlliance A222001: Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer.PMC12871868UG1 CA189823UG1 CA239758UG1 CA239769UG1 CA239762UG1 CA189858Chow SDiaz Pardo DANauseef JTHumeniuk MSTofthagen CAdams-Campbell LLHuang AJStish BJLoprinzi CLMazza GLNaha KTagawa STNovotny PJSmith TJChay CLustberg MBRuddy KJfalseAlliance A222001: Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer.<h4>Purpose</h4>Hot flashes are a common side effect reported by men receiving androgen-deprivation therapy (ADT) for the treatment of prostate cancer. We sought to determine whether oxybutynin could improve hot flash symptoms in men with prostate cancer.<h4>Patients and methods</h4>Patients with prostate cancer receiving a stable regimen of ADT with at least 28 hot flashes per week were randomly assigned to receive either oxybutynin 2.5 mg twice daily, oxybutynin 5 mg twice daily, or matching placebo for 6 weeks. The primary end point was the change in patient-reported hot flash scores since baseline at 6 weeks. Additional outcomes included incidence of adverse events (AEs), changes since baseline in Hot Flash-Related Daily Interference Scale (HFRDIS) scores, and patient-reported symptoms2026-01-01T00:00:00Z2026 Jan2026-07-15T12:08:29.309Z2026-07-04T03:11:37.483ZS-EPMC128718684158737010.1200/JCO-25-0148610.1200/jco-25-01486